In a cohort of 1083 stroke patients, Poppe et al. [78] reported that admission hyperG [>144 mg/dL (>8.0 mmol/L)] was associated with greater risk of ICH, mortality, and poor 90-day outcome after intravenous tissue plasminogen activator (TPA). The gene discussed is PLAT; the disease is Stroke.